Anke Richters, PhD

GU Oncology Now

Anke Richters, PhD, from the Netherlands Comprehensive Cancer Organization, discusses how often primary end points are altered during clinical trials and why these changes may occur.Among the trials that Dr. Richters and colleagues examined, 63% had altered end points. The trials, including IMvigor130, IMvigor211, KEYNOTE-045, and KEYNOTE-361, involved the investigation of immune checkpoint inhibitors in urothelial cancer. Most of the end point changes were related to the addition of a second outcome or multiple comparisons of different biomarkers.Many end point alterations are not reported and can lead to downsides, such as a lack of quality control.

Undisclosed Primary End Point Changes Affect Clinical Trials

Urothelial Carcinoma

Anke Richters, PhD, of the Netherlands Comprehensive Cancer Organization, discusses why and how often primary end points are altered during clinical trials.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe